Палин

Quick links to important sections

Палин

Treatment option: Prostatitis, Urethritis, Cystitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Палин

Property Description
Active ingredient Pipemidic Acid (Пипемидовая кислота)
Form Oral Capsule
Pharmacological class Quinolone Antibacterial Agent
General purpose Fighting systemic bacterial infections
Origin Synthetic compound

Палин (PaliN): What is this Antibacterial Agent?

Палин is a specific synthetic pharmaceutical preparation containing the single active ingredient, Pipemidic Acid. This medicine is classified as an antibacterial agent, belonging to the quinolone group of medicines. The drug is primarily manufactured as an oral capsule, intended for systemic absorption rather than localized, surface treatment. Pipemidic Acid is specifically a second-generation, non-fluorinated quinolone, which differentiates its structure and spectrum of activity from the later fluoroquinolones. This classification emphasizes its dedicated, prescription-only role in fighting microbial imbalances within the body.

Pipemidic Acid is clinically recognized for its efficacy against a range of Gram-negative pathogens, supporting its use in certain systemic infection scenarios.

Pipemidic Acid: Understanding Its Core Function and Purpose

The fundamental purpose of Палин is to resolve certain bacterial infections by exerting a potent bactericidal action against susceptible microorganisms. This effect is achieved because Pipemidic Acid interferes directly with a vital bacterial enzyme known as DNA gyrase (or bacterial topoisomerase II). This enzyme is essential for bacteria to efficiently copy and repair their genetic material. By halting this core reproductive process, the active substance effectively causes cell death.

The substance is known for achieving high concentrations in the urine and bile, a property that makes it clinically relevant for addressing infections specifically within the urinary and biliary systems. This targeted, systemic action provides the specific therapeutic benefit of microbial clearance.

What side effects are possible with Палин?

Possible Side Effects and Safety Information

The safety profile of Palin (Pipemidic Acid) is officially documented based on its classification as a quinolone antibacterial agent. The possible adverse effects are categorized by the physiological systems they affect, with specific serious and long-lasting reactions noted across the quinolone class by international regulatory agencies.


Key Adverse Reaction Categories

Adverse effects are often grouped into System-Organ Classes (SOCs) for reporting. Commonly reported effects in regulatory documents often involve the Gastrointestinal System (e.g., nausea, diarrhea, abdominal discomfort) and the Nervous System (e.g., dizziness, headache). Reactions involving the Skin and Subcutaneous Tissue (e.g., photosensitivity, allergic reactions) are also documented.

Serious Safety Concerns

Official regulatory reviews have identified risks of serious, potentially disabling, and long-lasting adverse reactions associated with Pipemidic Acid. These primarily include effects on the Musculoskeletal System, such as tendinitis and tendon rupture, and the Nervous System, including peripheral neuropathy (nerve damage) and serious central nervous system events like convulsions.

Population-Specific Safety and Restrictions

Specific patient groups are noted to be at increased risk. Older patients and those with impaired renal function are cited as having a higher potential for tendon injury. Use of the medicine is generally restricted for pediatric patients due to concerns over joint safety. Furthermore, official labeling lists contraindications against use in conditions such as acute porphyria or carnitine deficiency. The onset of serious effects like tendon damage is documented as occurring shortly after initiation or being delayed for several months after stopping treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Pipemidic Acid describe a potential acute overdose profile characterized primarily by effects on the central nervous system (CNS) and the gastrointestinal (GI) tract. Documented manifestations may include nausea, vomiting, and abdominal pain, alongside CNS effects such as dizziness, tremor, and mental confusion.

Documented Manifestations and Severe Outcomes

Excessive exposure is officially documented to carry the risk of severe neurological outcomes, including convulsions and potentially status epilepticus. Overdose may also require management for potential renal impairment. A specific caution notes that the severity of overdose effects may be increased in patients with pre-existing renal impairment.

Regulator-Mandated Emergency Actions

Due to the risk of severe escalation, regulatory authorities mandate that immediate medical attention must be sought for any symptomatic overdose. Individuals observing severe CNS signs or symptoms must contact emergency services immediately. The regulatory information confirms that no specific antidote is known for Pipemidic Acid.

Management Procedures

Treatment is strictly limited to symptomatic and supportive treatment. Procedures documented to reduce absorption may include gastric lavage or administration of activated charcoal, with monitoring of vital functions being required during hospital observation.

Therapeutic Uses of Палин

Main Indications for Use

Palin is an antibacterial medication containing pipemidic acid, belonging to the quinolone group. It is primarily used in the treatment of inflammatory diseases affecting the urinary tract and prostate. The medication is effective against a variety of Gram-negative and some Gram-positive bacteria that commonly cause these infections.

Acute and Chronic Urinary Tract Infections

The medication is frequently prescribed for both sudden-onset and long-term recurring infections of the lower urinary tract. These conditions include:

  • Cystitis: Inflammation of the bladder, often characterized by frequent, painful urination.
  • Urethritis: Inflammation of the urethra, the tube that carries urine out of the body.
  • Pyelonephritis: In certain clinical scenarios, it may be used for infections of the kidneys, particularly when the causative organisms are susceptible to pipemidic acid.

Prostatitis

Palin is also utilized in the management of prostatitis, which is the inflammation of the prostate gland. Its properties allow it to reach therapeutic concentrations in the prostate tissue, making it a viable option for treating bacterial infections in this area.

Therapeutic Benefits

The primary benefit of Palin lies in its targeted action within the urinary system. Unlike broad-spectrum antibiotics that affect the entire body significantly, pipemidic acid concentrates specifically in the urine.

  • High Concentration in Urine: The active substance is excreted by the kidneys in its active form, ensuring that the medication reaches the site of infection in high enough concentrations to inhibit bacterial growth.
  • Management of Chronic Conditions: Because it can be used for chronic infections, it plays a role in reducing the frequency of relapses in patients prone to recurrent urinary tract issues.
  • Bactericidal and Bacteriostatic Action: Depending on the concentration and the type of bacteria, the medication can either stop the growth of bacteria or destroy them entirely.

Eligibility and Restrictions for Use

The eligibility profile for Палин (Pipemidic Acid) is defined by severe regulatory restrictions and numerous absolute contraindications. The European Medicines Agency (EMA) recommended the suspension of its marketing authorization due to the risk of disabling and potentially permanent side effects, which is the principal constraint on its use.

Populations for whom use is Contraindicated

The medicine is absolutely prohibited for patients with a known hypersensitivity to pipemidic acid or any other quinolone. It is also contraindicated in those with a history of tendon disorders related to previous quinolone use.

Population Group Eligibility Status
Children and Adolescents Contraindicated (Must not be used).
Pregnant Women Contraindicated (Due to class risk of joint damage).
Breastfeeding Women Contraindicated (Must not be used).

Populations Requiring Special Caution

Use of this medicine requires special caution in older adults, patients with kidney impairment, and individuals who have had an organ transplant, as these groups are at a higher risk of severe tendon damage. Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are advised to avoid this medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Pipemidic Acid by identifying specific drug classes and conditions where co-administration presents a documented risk.


Pharmacodynamic Interaction Restrictions

Interacting Substance Official Restriction Outcome as Documented Population Constraint
Corticosteroids Combined use should be avoided. Documented increased risk of tendon injury and tendinopathy. Risk is heightened in elderly and patients with kidney disease.
Oral Anticoagulants Requires monitoring. Reportedly increases the activity of the anticoagulant, potentially affecting the International Normalized Ratio (INR). None documented.

Formal Contraindication

Administration of Pipemidic Acid is formally contraindicated during lactation, a restriction explicitly stated in the Summary of Product Characteristics (SmPC).

Regulatory authorities define this interaction structure through two main pharmacodynamic risks: an avoidance requirement for combined use with Corticosteroids due to musculoskeletal hazard, and a monitoring requirement for co-administration with Oral Anticoagulants due to potential coagulation imbalance. The official profile further includes specific risk stratification for the tendon-related interaction.

Mechanism of Action

How Палин Works: Mechanism of Action

Палин (Pipemidic acid) exerts its effect by acting as a Type II Topoisomerase inhibitor. Its primary biological targets are two essential bacterial enzymes: DNA gyrase and Topoisomerase IV . These enzymes are critical for managing the bacterial cell's genetic material, enabling the unwinding, copying, and repair of DNA.

The drug interferes with these processes by binding to the DNA-enzyme complex, which stabilizes the complex in a cleaved state. This action causes irreparable double-strand breaks in the bacterial DNA, initiating a rapid, toxic intracellular cascade. This damage halts the fundamental processes of DNA replication and transcription, ultimately leading to the programmed destruction of the bacterial cell (bactericidal mechanistic class).

Furthermore, the active compound is minimally metabolized and largely excreted by the kidneys, resulting in its high concentration within the urinary system. This physiological localization concentrates the inhibitory action, resulting in a quantifiable decrease in the population of susceptible bacteria in that environment.

Dosage and Administration Information

How to use Палин — Administration Guidelines

Administration Scope

Instruction Details
Route of administration Oral administration using the 400 mg unit strength capsule or tablet.
Dosing schedule The standard adult daily dose is 800 mg, typically delivered as 400 mg per single dose.
Timing in relation to meals The medication is often taken on a structured schedule to maintain steady concentrations.
Preparation requirements The oral form must be taken with a sufficient amount of fluid to assist proper administration.
Age-group administration rules The use of Pipemidic Acid is generally contraindicated in children and adolescents.
Special procedural conditions In cases of mild renal insufficiency, dose adjustment is usually not necessary to maintain effective drug levels.

Instruction Classifications

Classification Detail
Administration method type Oral
Frequency pattern Twice daily (b.i.d.)
Use-context constraints Must be taken with adequate hydration and is contraindicated in pediatric patients.

Resulting Procedural Structure

Step sequence:

  • Take the 400 mg unit dose of the oral medicine with a sufficient amount of water.
  • Administer the dose twice daily to meet the total daily 800 mg regimen and achieve therapeutic steady state.
  • Adhere to the prescribed duration of the treatment course, which is typically 7 to 10 days.

Connection to the overall use protocol: The usage protocol specifies an oral route with a defined 400 mg unit strength to be taken twice daily to ensure sustained therapeutic concentration. In patients presenting with mild renal impairment, no dosage reduction is typically required to maintain effective levels. The instructions confirm that the drug is contraindicated for use in children and adolescents, setting a boundary for patient eligibility. The administration is structured as a short-term course.

Recent Clinical Evidence

Palin (Pipemidic Acid): Recent Clinical Evidence

Palin is a brand name for the antibiotic pipemidic acid, which belongs to the class of quinolone antibacterials. Its primary historical use has been for the treatment of urinary tract infections (UTIs) caused by susceptible Gram-negative and some Gram-positive bacteria. Pipemidic acid is concentrated in the urine, making it particularly effective for this indication.


Efficacy and Comparative Studies

Clinical trials, including older comparative studies, have shown that pipemidic acid is an effective option for treating uncomplicated lower UTIs in women, often demonstrating results comparable to other established antibiotics like nitrofurantoin over a 10-day course of therapy. Studies in children with acute UTIs have also indicated a high rate of bacterial clearance, suggesting its effectiveness in pediatric cases, though this use is generally subject to specific restrictions due to class effects on juvenile joints observed in animal studies.


Safety Profile and Regulatory Status

Recent regulatory reviews, particularly in Europe, have led to significant changes in the marketing status of pipemidic acid due to concerns over the safety of the quinolone and fluoroquinolone class. The European Medicines Agency (EMA) has recommended the suspension of marketing authorizations for medicines containing pipemidic acid and several other older quinolones. This action was based on the risk of serious, disabling, and potentially long-lasting side effects that primarily affect the musculoskeletal and nervous systems. These adverse effects can include tendonitis, tendon rupture, joint pain (arthralgia), muscle weakness, and peripheral neuropathy (e.g., tingling or burning pain).

Consequently, the clinical use of pipemidic acid has been significantly curtailed in many regions due to the availability of newer antibiotics with a more favorable safety profile, particularly for common, uncomplicated infections. Current clinical development focuses less on its existing applications and more on the potential of new derivatives or novel formulations to enhance its antibacterial activity or overcome limitations like low solubility, with some preclinical work exploring its potential in areas such as oncology.

Key Studies & References A New Approach for Improving the Antibacterial and Tumor Cytotoxic Activities of Pipemidic Acid by Including It in Trimethyl-β-cyclodextrin (Preclinical work on novel formulations)

Frequently Asked Questions (FAQ)

Common questions about Палин (FAQ)

Q: Can I take Palin if I have kidney problems?

A: Official documentation indicates that dose adjustment is generally not required for patients with mild kidney impairment. However, official documentation also lists patients with impaired renal function among those who should be monitored closely due to a documented increased risk of severe effects, such as tendon injury.

Q: Does Palin cause drowsiness?

A: Documented adverse reactions involving the nervous system include dizziness and headache, which may lead to impaired mental alertness. Regulatory documents generally contain warnings regarding activities that require full mental alertness.

Q: What should I do if Palin causes me nausea?

A: Nausea is officially noted as a commonly reported adverse effect involving the gastrointestinal system, as noted in official regulatory documents. For any clinical review of symptoms, official guidance often references consulting a healthcare professional.

Q: How does Palin differ from broad-spectrum antibiotics?

A: Palin (Pipemidic Acid) is classified as a quinolone antibacterial agent. It is characterized by a potent action that is primarily effective against susceptible Gram-negative organisms, rather than a broad range of bacteria. The substance is also known for achieving high concentrations in the urine, making it suitable for specific types of infections.

Q: Can Palin cause allergic reactions?

A: Yes, regulatory documents list allergic reactions involving the skin as possible adverse effects of the medicine. Furthermore, a known hypersensitivity (a severe allergic reaction) to Pipemidic Acid or any other drug in the quinolone class is listed as an absolute contraindication for use.

Q: What is the main difference between Palin and other uroseptics?

A: Palin is a quinolone antibacterial agent, which means its action is based on interfering with essential bacterial enzymes, specifically DNA gyrase. This specific mechanism of action and its classification distinguish it from other medicinal classes that are also used for treating urinary tract infections (uroseptics).

Q: Is it necessary to adjust the dose of Palin if I have other illnesses?

A: Official guidelines state that dose adjustment is typically not required for mild kidney impairment. For most other serious co-existing conditions, official documentation generally does not specify a simple dose change, instead listing them as contraindications or caution areas.

Q: Can Palin cause dizziness or affect my ability to drive?

A: The medicine has documented adverse effects on the nervous system, including dizziness and the possibility of serious central nervous system events. Due to these potential effects on mental alertness, regulatory documents generally contain warnings regarding the ability to drive or operate complex machinery.

Q: What should I do if I experience unusual symptoms while taking Palin?

A: Official regulatory warnings note the risk of serious, potentially disabling, and long-lasting adverse effects on the musculoskeletal and nervous systems. Official warnings describe these symptoms as events that warrant prompt clinical review when they occur.

Q: What is the difference between Palin and Nolicin (Norfloxacin)?

A: Palin (Pipemidic Acid) and Nolicin (Norfloxacin) are both classified within the quinolone family of antibacterial agents. They share a similar mechanism of action that works by targeting essential bacterial enzymes, such as DNA gyrase. This shared classification and function connect the two medicines.

Q: Can I take Palin with dairy products?

A: As an agent belonging to the quinolone class of medicines, Pipemidic Acid may interact with the calcium and other polyvalent minerals found in dairy products. This type of interaction can potentially lead to decreased absorption of the medicine, reducing its effectiveness.

Q: How long does it take for Palin to start working?

A: The medicine’s action at the cellular level, which involves halting bacterial DNA synthesis, begins quickly. Studies show that maximum concentrations of the active substance in the blood are documented to be achieved within hours of administration.

Q: Can I take Palin with food?

A: Official guidelines for administration emphasize taking the medicine on a structured schedule to maintain steady concentrations in the body. The medicine is directed to be taken with a sufficient amount of water.

Q: Can I take Palin and alcohol simultaneously?

A: There are documented adverse effects on the nervous system, such as dizziness. The simultaneous consumption of alcohol may worsen these effects, according to general regulatory principles for medications affecting the central nervous system.

Q: Does Palin interact with birth control pills?

A: Official clinical guidance from intergovernmental health bodies typically indicates that quinolone antibacterial agents, in general, do not interfere with the effectiveness of combined hormonal contraceptives.

Q: What should I do if I miss a dose of Palin?

A: The general guideline for twice-daily medication is to take the dose as soon as it is remembered, provided the next dose is not due soon. Regulatory guidelines state that a double dose should not be taken to compensate for a single missed dose.

Q: What is known about Palin's safety for the liver?

A: Official contraindications for the medicine include conditions such as acute porphyria and carnitine deficiency, both of which relate to overall metabolic function. However, the primary regulatory documentation does not detail general safety warnings specifically targeted at hepatic impairment.

Q: How quickly does the effect wear off after stopping Palin?

A: Pharmacokinetic studies, which describe how the body processes the drug, indicate that the active substance has a biological half-life. This half-life, which measures the time required for the amount of drug in the body to be reduced by half, ranges between approximately 5.7 and 16 hours.

Q: Is Palin compatible with vitamins?

A: Regulatory documents note that other medicines in the quinolone class may interact with polyvalent cations. These are minerals such as calcium, iron, or zinc, which are commonly found in many mineral or multivitamin supplements. Such interactions can affect how the medicine is absorbed.

Q: What is the risk of bacteria developing resistance to Palin?

A: Bacterial resistance mechanisms are a subject of ongoing research for all quinolone antibacterial agents, including Pipemidic Acid. Regulatory and scientific bodies note that completing the full prescribed treatment course is necessary to minimize the risk of bacteria developing resistance.

Q: Does Palin have a post-antibiotic effect?

A: Scientific literature and regulatory documents recognize the Postantibiotic Effect (PAE) as a phenomenon observed across various antibacterial classes, including quinolones. The PAE is the temporary suppression of bacterial growth that may continue after drug concentration has dropped below the minimum effective level.

Q: Why is it important to complete the full course of Palin, even if I feel better?

A: Official administration instructions note that adherence to the full prescribed duration is required to support microbial clearance and minimize the risk of bacterial resistance development.

How should Палин be stored and disposed of?

The storage and disposal of Палин (Pipemidic Acid) must follow strict requirements outlined in official regulatory labeling to ensure product stability and public safety.

Official Storage and Handling

Requirement Type Official Regulatory Statement
Storage Temperature Store at room temperature, typically not exceeding 25 C or 30 C.
Protection Requirements Must be sheltered from light and protected from moisture.
Child Safety Must be kept out of the sight and reach of children and stored securely.
Container Rule Store in the original package and keep container tightly closed.

Official Disposal Rules

Unused or expired doses must be disposed of in accordance with local regulations or returned through an approved waste disposal program. The product should not be released into the environment (e.g., flushed down the toilet or placed in the trash) unless the regulatory labeling explicitly instructs otherwise, aligning with general pharmaceutical waste protocols. These constraints are mandated to preserve the medicine's integrity and mitigate risks of contamination or accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Палин found in:

A-Z Index: